CryoPort Issues Letter to Shareholders

BREA, CA -- (MARKET WIRE) -- 01/22/07 -- CryoPort, Inc. (PINKSHEETS: CYRX) released a letter to shareholders today.

To CryoPort Shareholders,

As we begin the New Year, I am growing more confident that we are entering a new stage in our business cycle. CryoPort's early years of business operations were primarily focused on research and development and the subsequent manufacture and sales of some of the industry's leading cryogenic shipping vessels. At times it has been difficult to meet all of the challenges with which we were presented, but it was those very challenges that led us to where we are today.

We recently announced that we have completed the development of the CryoPort Express® One-Way Shipper System in the 5-liter configuration. We will be complementing this configuration with additional sizes in the future. We are developing the program and working with select biopharmaceutical companies who have indicated a desire to be part of a pilot program. Interestingly enough, many of these clients contacted CryoPort on an unsolicited basis to initiate the relationship. I view this as a positive response of how industry leaders, and our future clients, view our exciting new product line.

The need to ship low dose, high value drugs is something that the pharmaceutical industry is only now beginning to recognize. As more specialty drugs are developed, the need for our products will increase accordingly. In order for CryoPort to reach the level that I believe is achievable, it will be necessary to develop a number of strategic relationships. Initially, CryoPort was focused on research and development. Successful product development led to the need for low quantity, highly specialized manufacturing, as well as the need for a sales and marketing group. We are now entering a phase in our business cycle where we will need high quantity manufacturing and a robust logistics platform to ensure we will have the capacity to meet the expected demand for our products going forward.

We recently announced that we had signed a Letter of Intent between CryoPort and VHS Group, LLC, dba Commodity Sourcing Group ("CSG"). I believe that this relationship will establish the cornerstone for our logistics operations that will be imperative for a successful launch of the CryoPort Express® One-Way Shipper System. CSG has a number of clients that are tied into the very industries to which we cater and we look forward to finalizing this relationship in the near future.

In past letters I have touched on our continuous efforts to be traded on a more transparent trading platform. In order to accomplish this, we needed to have a broker/dealer file a 15c2-11 form with the NASD. On Friday January 12, 2007 a NASD member firm filed a 15c2-11 with the NASD requesting the ability to act as a market maker for our common stock on an unsolicited basis. We will work closely with this firm to insure that the process is completed in the most expedited manner possible. As CryoPort is a fully reporting company with the SEC, upon acceptance of the 15c2-11 we will request that our stock be traded on the NASD OTC Bulletin Board. Once we meet the listing requirements of a senior exchange, we will again make application to list our common stock on a higher trading platform.

I am excited about the developments that are beginning to unfold here at CryoPort. Our staff has worked diligently over the past two years to continue to move the Company forward. The Company's future is bright and the staff is committed to achieving a new standard of excellence in the low-temperature shipping industry. We will keep our investors updated as developments occur.


Peter Berry

About CryoPort, Inc.

CryoPort ( develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical sectors. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery components that make up the foundation of the biopharmaceutical and biotechnology industries.


This press release contains forward-looking statements. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Investor Relations:
First Capital Investors, Inc.
Trey Meehan
Email Contact